N-acetyl cysteine in schizophrenia: A double blind randomised placebo controlled trial

N-acetyl cysteine in Schizophrenia:A double blind randomised placebo controlled trial investigating a range of psychiatric rating scales

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000363684

Enrollment

150

Registered

2005-09-12

Start date

2002-01-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

This is a six month study with a four to six week post-disconinuation visit. The trial involves taking 2g of n-acetyl cysteine per day in addition to the participant's usual treatment.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

DSM-IV diagnosis of schizophrenia, have a PANSS score of >55 or at least two items in the positive and/or negative items being >3 AND/OR have a CGI-S >3, be utilising effective contraception if of child-bearing age.

Exclusion criteria

Taking mood stabilisers, asthma or history of respiratory insufficiency/allergy to n-acetyl cysteine, abnormal heamotological findings, or systemic medical disorder, currently taking either 500mg of NAC/day, 200ug of selenium/day or 500 IU of Vitamin E/day or inability to comply with the informed consent.

Outcome results